MX2023013744A - Composiciones farmaceuticas que comprenden un modulador del receptor de rianodina y sus usos. - Google Patents

Composiciones farmaceuticas que comprenden un modulador del receptor de rianodina y sus usos.

Info

Publication number
MX2023013744A
MX2023013744A MX2023013744A MX2023013744A MX2023013744A MX 2023013744 A MX2023013744 A MX 2023013744A MX 2023013744 A MX2023013744 A MX 2023013744A MX 2023013744 A MX2023013744 A MX 2023013744A MX 2023013744 A MX2023013744 A MX 2023013744A
Authority
MX
Mexico
Prior art keywords
pharmaceutical compositions
receptor modulator
ryanodine receptor
disease
present disclosure
Prior art date
Application number
MX2023013744A
Other languages
English (en)
Spanish (es)
Inventor
Eugene E Marcantonio
Mette Uhre Anby
Jerome Binet
Original Assignee
Armgo Pharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Armgo Pharma Inc filed Critical Armgo Pharma Inc
Publication of MX2023013744A publication Critical patent/MX2023013744A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/554—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one sulfur as ring hetero atoms, e.g. clothiapine, diltiazem
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
    • A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2886—Dragees; Coated pills or tablets, e.g. with film or compression coating having two or more different drug-free coatings; Tablets of the type inert core-drug layer-inactive layer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Neurology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Inorganic Chemistry (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Diabetes (AREA)
  • Cardiology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Hospice & Palliative Care (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
MX2023013744A 2021-05-20 2022-05-19 Composiciones farmaceuticas que comprenden un modulador del receptor de rianodina y sus usos. MX2023013744A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202163191142P 2021-05-20 2021-05-20
PCT/US2022/030111 WO2022246114A2 (en) 2021-05-20 2022-05-19 Pharmaceutical compositions comprising a ryanodine receptor modulator and uses thereof

Publications (1)

Publication Number Publication Date
MX2023013744A true MX2023013744A (es) 2023-12-04

Family

ID=84141833

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2023013744A MX2023013744A (es) 2021-05-20 2022-05-19 Composiciones farmaceuticas que comprenden un modulador del receptor de rianodina y sus usos.

Country Status (11)

Country Link
US (4) US11717526B2 (cg-RX-API-DMAC7.html)
EP (1) EP4340861A4 (cg-RX-API-DMAC7.html)
JP (1) JP2024519917A (cg-RX-API-DMAC7.html)
KR (1) KR20240040681A (cg-RX-API-DMAC7.html)
CN (1) CN117750966A (cg-RX-API-DMAC7.html)
AU (1) AU2022279235A1 (cg-RX-API-DMAC7.html)
BR (1) BR112023024170A2 (cg-RX-API-DMAC7.html)
CA (1) CA3176718A1 (cg-RX-API-DMAC7.html)
IL (1) IL308481A (cg-RX-API-DMAC7.html)
MX (1) MX2023013744A (cg-RX-API-DMAC7.html)
WO (1) WO2022246114A2 (cg-RX-API-DMAC7.html)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2022150603A1 (en) * 2021-01-08 2022-07-14 Armgo Pharma, Inc. Crystalline forms of a ryanodine receptor modulator and uses thereof
EP4433062A4 (en) * 2021-11-16 2025-10-22 Rycarma Therapeutics Inc THERAPEUTIC COMPOUNDS

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5920219A (ja) * 1982-07-26 1984-02-01 Shin Etsu Chem Co Ltd 腸溶性コ−テイング製剤の製造方法
US4775536A (en) * 1986-02-24 1988-10-04 Bristol-Myers Company Enteric coated tablet and process for making
US8022058B2 (en) 2000-05-10 2011-09-20 The Trustees Of Columbia University In The City Of New York Agents for preventing and treating disorders involving modulation of the RyR receptors
US7718644B2 (en) * 2004-01-22 2010-05-18 The Trustees Of Columbia University In The City Of New York Anti-arrhythmic and heart failure drugs that target the leak in the ryanodine receptor (RyR2) and uses thereof
JP4414237B2 (ja) 2002-03-20 2010-02-10 テバ ファーマシューティカル インダストリーズ リミティド ケチアピンヘミフマレートの結晶形
US8710045B2 (en) 2004-01-22 2014-04-29 The Trustees Of Columbia University In The City Of New York Agents for preventing and treating disorders involving modulation of the ryanodine receptors
US7704990B2 (en) 2005-08-25 2010-04-27 The Trustees Of Columbia University In The City Of New York Agents for preventing and treating disorders involving modulation of the RyR receptors
US20100297226A1 (en) * 2006-06-01 2010-11-25 Dexcel Pharma Technologies Ltd. Multiple unit pharmaceutical formulation
WO2008060332A2 (en) 2006-06-02 2008-05-22 The Trustees Of Columbia University In The City Of New York Methods for treating or reducing muscle fatigue
WO2008021439A2 (en) 2006-08-17 2008-02-21 The Trustees Of Columbia University In The City Of New York Compositions and methods for treatment of cardiac hypertrophy
WO2008021432A2 (en) 2006-08-17 2008-02-21 The Trustees Of Columbia University In The City Of New York Compositions and methods for treatment of conditions affecting the nervous system
WO2008144483A2 (en) 2007-05-18 2008-11-27 Armgo Pharma, Inc. Agents for treating disorders involving modulation of ryanodine receptors
EA028108B1 (ru) 2008-03-03 2017-10-31 Армго Фарма, Инк. Способ получения бензотиазепинов из гамма-аминоалкилбензолов
WO2012037105A1 (en) 2010-09-14 2012-03-22 The Trustees Of Columbia University In The City Of New York Methods of treating, ameliorating or preventing stress-induced neuronal disorders and diseases
EP2708535A1 (en) * 2012-05-11 2014-03-19 Les Laboratoires Servier Agents for treating disorders involving modulation of ryanodine receptors
WO2015106268A1 (en) * 2014-01-13 2015-07-16 Ironwood Pharmaceuticals, Inc. USE OF sGC STIMULATORS FOR THE TREATMENT OF NEUROMUSCULAR DISORDERS
WO2016109596A1 (en) 2014-12-30 2016-07-07 Myotherix, Inc. Novel calcium modulators
JP6954927B2 (ja) * 2016-02-09 2021-10-27 アルビレオ・アクチボラグ 経口コレスチラミン製剤及びその使用

Also Published As

Publication number Publication date
US11717526B2 (en) 2023-08-08
EP4340861A2 (en) 2024-03-27
BR112023024170A2 (pt) 2024-02-06
CA3176718A1 (en) 2022-11-20
EP4340861A4 (en) 2025-05-28
WO2022246114A3 (en) 2022-12-15
CN117750966A (zh) 2024-03-22
US20230364107A1 (en) 2023-11-16
WO2022246114A2 (en) 2022-11-24
JP2024519917A (ja) 2024-05-21
US20230372358A1 (en) 2023-11-23
KR20240040681A (ko) 2024-03-28
US12161650B2 (en) 2024-12-10
US12059426B2 (en) 2024-08-13
IL308481A (en) 2024-01-01
US20220387442A1 (en) 2022-12-08
AU2022279235A1 (en) 2023-12-07
US20250302847A1 (en) 2025-10-02

Similar Documents

Publication Publication Date Title
CL2023000516A1 (es) Compuestos como agonistas de glp-1r
Durgam et al. An 8-week randomized, double-blind, placebo-controlled evaluation of the safety and efficacy of cariprazine in patients with bipolar I depression
CL2024000861A1 (es) Ácidos carboxílicos de benzimidazol como agonistas de glp-1r
CR20220558A (es) Compuestos, composiciones farmacéuticas y métodos para la preparación de compuestos y para su uso
MX2019007119A (es) Preparado oral del activador de glucocinasa y preparacion del mismo.
EP4563150A3 (en) New crystalline forms of n-(3-(2-(2-hydroxyethoxy)-6-morpholinopyridin-4-yl)-4-methvlphenyl)-2(trifluoromethyl) isonicotinamide as raf inhibitors for the treatment of cancer
ECSP19078393A (es) Compuestos inhibidores de ask1 y usos de los mismos
BR112023024170A2 (pt) Composições farmacêuticas compreendendo um modulador do receptor da rianodina e usos das mesmas
BRPI0704238A (pt) preventivo da doença de coccidiose e clostrìdica e/ou terapia para a doença de coccidiose e clostridica
DOP2013000263A (es) Compuestos de 2- (2,4,5-anilino sustituido) pirimidina derivados como moduladores de egfr utilizados para el tratamiento del cáncer
UY26130A1 (es) Compuestos para tratar la obesidad
ECSP20068210A (es) Moduladores calpaína y usos terapéuticos de los mismos
AR098599A2 (es) Procedimiento de utilización de una composición farmacéutica que comprende derivados de carboestirilo e inhibidores de la reabsorción de serotonina para preparar un medicamento para el tratamiento de trastornos del animo
MX2023008671A (es) Composicion farmaceutica.
CO2019002673A2 (es) Derivados de cromano, isocromano y dihidroisobenzofuranos como moduladores alostéricos negativos de mglur2, composiciones y su uso
BR112022021640A2 (pt) Usos e formulações de canabinoides
Mowla et al. Topiramate augmentation in patients with resistant major depressive disorder: a double-blind placebo-controlled clinical trial
PA8587201A1 (es) Derivados terapeuticos de prolina
SV2001000465A (es) Combinacion de secretagogos de hormona del crecimiento y antidepresivos ref. pc10733/20144/bb
EP1634596A4 (en) APORPHINE AND OXOPHORPHINE AND ITS MEDICAL USE
Maged Antipsychotic and anticholinergic drugs
Kinslow et al. Acute hypertensive crisis and severe headache after concurrent use of armodafinil and tranylcypromine: case report and review of the literature
AR099872A1 (es) Formulaciones de progesterona
Gören et al. Psychotropics and sudden cardiac death
AR036677A1 (es) Uso de aminometilcromanos sustituidos para la elaboracion de un medicamento, un procedimiento para la preparacion de estos compuestos y las composiciones farmaceuticas que contienen estos compuestos en calidad de principios activos